MRSA/MSSA Screening Test
The Company has also developed a nasal screening test for use in the rapid and direct detection of S. aureus and determination of methicillin resistance/susceptibility using nasal swabs from patients. This screening test is similar in design to the Company's blood culture test. It will help hospitals identify carriers of MRSA or MSSA bacteria and enable patient management that could reduce the incidence of infections. This test can also be used by surgeons to screen patients prior to surgery in order to direct pre-surgical decolonization procedures and/or perioperative antibiotic selection. The MicroPhage test is expected to have significant cost and performance advantages over molecular tests such as polymerase chain reaction ("PCR") and other methodologies.
This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.